Annual FCF
N/A
December 1, 2024
Summary
- VKTX annual free cash flow is not available.
Performance
VKTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly FCF
N/A
December 1, 2024
Summary
- VKTX quarterly free cash flow is not available.
Performance
VKTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM FCF
N/A
December 1, 2024
Summary
- VKTX TTM free cash flow is not available.
Performance
VKTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
VKTX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | - | - | - |
| 5 y5 years | - | - | - |
VKTX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time |
Viking Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$21.96 M(-23.0%) | -$74.25 M(+3.2%) |
| Jun 2024 | - | -$28.51 M(+364.8%) | -$71.94 M(+31.1%) |
| Mar 2024 | - | -$6.13 M(-65.2%) | -$54.87 M(-25.2%) |
| Dec 2023 | -$73.38 M(+51.6%) | -$17.64 M(-10.3%) | -$73.38 M(+10.1%) |
| Sep 2023 | - | -$19.66 M(+71.9%) | -$66.66 M(+10.2%) |
| Jun 2023 | - | -$11.44 M(-53.6%) | -$60.50 M(-3.2%) |
| Mar 2023 | - | -$24.64 M(+125.5%) | -$62.51 M(+29.2%) |
| Dec 2022 | -$48.40 M(+1.7%) | -$10.93 M(-19.1%) | -$48.40 M(-2.9%) |
| Sep 2022 | - | -$13.50 M(+0.4%) | -$49.82 M(+5.4%) |
| Jun 2022 | - | -$13.44 M(+27.7%) | -$47.25 M(+0.0%) |
| Mar 2022 | - | -$10.53 M(-14.7%) | -$47.24 M(-0.7%) |
| Dec 2021 | -$47.59 M(+118.5%) | -$12.35 M(+13.0%) | -$47.59 M(+16.9%) |
| Sep 2021 | - | -$10.93 M(-18.7%) | -$40.72 M(+16.0%) |
| Jun 2021 | - | -$13.43 M(+23.5%) | -$35.12 M(+23.9%) |
| Mar 2021 | - | -$10.88 M(+98.3%) | -$28.35 M(+30.2%) |
| Dec 2020 | -$21.78 M(-12.0%) | -$5.49 M(+3.1%) | -$21.78 M(-22.3%) |
| Sep 2020 | - | -$5.32 M(-20.1%) | -$28.03 M(+7.4%) |
| Jun 2020 | - | -$6.67 M(+55.0%) | -$26.11 M(+0.8%) |
| Mar 2020 | - | -$4.30 M(-63.4%) | -$25.90 M(+4.6%) |
| Dec 2019 | -$24.75 M(+32.0%) | -$11.74 M(+245.6%) | -$24.75 M(+57.8%) |
| Sep 2019 | - | -$3.40 M(-47.4%) | -$15.69 M(-11.8%) |
| Jun 2019 | - | -$6.46 M(+104.9%) | -$17.79 M(+7.2%) |
| Mar 2019 | - | -$3.15 M(+17.7%) | -$16.60 M(-11.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$18.75 M(+27.1%) | -$2.68 M(-51.3%) | -$18.75 M(-6.3%) |
| Sep 2018 | - | -$5.50 M(+4.4%) | -$20.02 M(+12.2%) |
| Jun 2018 | - | -$5.27 M(-0.6%) | -$17.85 M(+6.4%) |
| Mar 2018 | - | -$5.30 M(+34.4%) | -$16.78 M(+13.7%) |
| Dec 2017 | -$14.76 M(+33.3%) | -$3.95 M(+18.6%) | -$14.76 M(+11.2%) |
| Sep 2017 | - | -$3.33 M(-20.8%) | -$13.28 M(+5.4%) |
| Jun 2017 | - | -$4.20 M(+28.1%) | -$12.60 M(+8.4%) |
| Mar 2017 | - | -$3.28 M(+33.1%) | -$11.63 M(+5.0%) |
| Dec 2016 | -$11.07 M(+26.8%) | -$2.46 M(-7.1%) | -$11.07 M(-7.0%) |
| Sep 2016 | - | -$2.65 M(-17.7%) | -$11.91 M(-5.9%) |
| Jun 2016 | - | -$3.23 M(+18.4%) | -$12.65 M(+14.5%) |
| Mar 2016 | - | -$2.73 M(-17.4%) | -$11.05 M(+26.5%) |
| Dec 2015 | -$8.73 M(+448.7%) | -$3.30 M(-3.0%) | -$8.73 M(+48.7%) |
| Sep 2015 | - | -$3.40 M(+109.8%) | -$5.87 M(+90.5%) |
| Jun 2015 | - | -$1.62 M(+294.4%) | -$3.08 M(+62.1%) |
| Mar 2015 | - | -$410.90 K(-6.8%) | -$1.90 M(+19.5%) |
| Dec 2014 | -$1.59 M(+1935.0%) | -$441.00 K(-27.7%) | -$1.59 M(+38.3%) |
| Sep 2014 | - | -$609.80 K(+38.6%) | -$1.15 M(+112.8%) |
| Jun 2014 | - | -$439.90 K(+336.4%) | -$540.70 K(+388.4%) |
| Mar 2014 | - | -$100.80 K(+918.2%) | -$110.70 K(+1018.2%) |
| Dec 2013 | -$78.20 K | - | - |
| Jun 2013 | - | -$9900.00(<-9900.0%) | -$9900.00(<-9900.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
FAQ
- What is the all time high annual FCF for Viking Therapeutics?
- What is the all time high quarterly FCF for Viking Therapeutics?
- What is the all time high TTM FCF for Viking Therapeutics?
What is the all time high annual FCF for Viking Therapeutics?
Viking Therapeutics all-time high annual free cash flow is -$78.20 K
What is the all time high quarterly FCF for Viking Therapeutics?
Viking Therapeutics all-time high quarterly free cash flow is $0.00
What is the all time high TTM FCF for Viking Therapeutics?
Viking Therapeutics all-time high TTM free cash flow is $0.00